Report questions FDA approval of controversial anticoagulant.
Seattle.
Michael
M
McCarthy
D000925:Anticoagulants / Q000494:pharmacology; D000069604:Dabigatran / Q000494:pharmacology*; D017277:Drug Approval / Q000458:organization & administration*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D011358:Product Surveillance, Postmarketing; D020521:Stroke / Q000517:prevention & control; D014481:United States
D000925:Anticoagulants; D000069604:Dabigatran